NIHON TRIM (6788) FY2027 Q1 Earnings Report

Quick View

Executive Summary

In addition to higher revenue and earnings, this quarter’s results featured a significant improvement in profit margins, with the qualitative improvement in profitability being the key highlight. Revenue was ¥6.73B (+13.1% YoY), Operating Income was ¥0.86B (+48.4%), Ordinary Income was ¥0.92B (+45.8%), and quarterly Net Income attributable to owners of the parent was ¥0.64B (+49.3%). The increase in earnings substantially exceeded the increase in revenue, and the Operating Income margin improved to 12.7%, up 3.0pt from 9.7% in the same period of the previous year. Growth in revenue and earnings in the core Water Healthcare Business, together with improved profitability in the Medical-Related Business, drove the results.

Factors Affecting Performance

【Revenue】Revenue was ¥6.73B, up +13.1% YoY. By segment, the Water Healthcare Business led company-wide growth with revenue of ¥5.98B (+15.2% YoY; 89.0% of the total), while the Medical-Related Business posted a slight decline in revenue to ¥0.75B (-1.0% YoY). Since the core business accounts for the majority of the revenue mix, demand trends in this business directly influence fluctuations in consolidated revenue.

【Profit and Loss】Operating Income was ¥0.86B (+48.4% YoY), significantly exceeding the growth in revenue. The gross profit margin remained high at 67.3%, and after deducting the SG&A expense ratio of 54.6%, the Operating Income margin improved to 12.7% (from 9.7% in the previous year, +3.0pt). Profit margins improved in both the Water Healthcare Business, to 13.1% (+2.6pt YoY), and the Medical-Related Business, to 9.2% (+5.5pt YoY), indicating that the increase in earnings resulted from simultaneous improvements in the profitability of both businesses. Ordinary Income was ¥0.92B (+45.8% YoY), while non-operating income and expenses generated a surplus of only ¥0.06B, indicating a limited contribution from activities outside the core business. Extraordinary gains and losses were immaterial, with virtually no impact from temporary factors. Net Income attributable to owners of the parent was ¥0.64B (+49.3% YoY), broadly consistent with the growth rate in Ordinary Income. Overall, these results represent higher revenue and earnings, with the earnings growth being of high quality, particularly because it was driven by improved core-business profitability.

Segment Analysis

The Water Healthcare Business generated revenue of ¥5.98B (+15.2% YoY) and segment profit of ¥0.79B (+43.5% YoY), making it the core earnings driver and accounting for 89.0% of consolidated revenue and approximately 92% of consolidated Operating Income. Its profit margin improved to 13.1% from 10.6% in the previous year, reflecting simultaneous growth in revenue and improvement in profitability. The Medical-Related Business posted a slight revenue decline to ¥0.75B (-1.0% YoY), but segment profit increased substantially to ¥0.07B (+144.7% YoY), with its profit margin improving significantly to 9.2% from 3.7% in the previous year. Profit margins rose in both businesses, and the increase in the consolidated Operating Income margin resulted from a combination of quantitative expansion in the core business and improved profitability in both businesses.

Key Financial Metrics

【Profitability】The company maintained its high-gross-margin structure, with an Operating Income margin of 12.7% (+3.0pt from 9.7% in the previous year), a Net Income margin of 7.9% (+1.2pt from 6.7% in the previous year), and a gross profit margin of 67.3%. 【Cash Flow Quality】Accounts receivable were ¥7.56B, large relative to revenue, while DSO was approximately 102 days and CCC was approximately 138 days, both relatively long. The speed of cash conversion during a period of revenue growth remains an ongoing area for monitoring. 【Investment Efficiency】Annualized ROE based on cumulative Q1 results was approximately in the mid-8% range, while ROA remained approximately around 6%. Financial leverage (total assets/net assets) was approximately 1.46x, a low level. Low total asset turnover is constraining improvement in ROE. 【Financial Soundness】The Equity Ratio was high at 68.4%, and the current ratio was 272.8%. Interest-bearing debt was primarily long-term borrowings of ¥1.00B, amounting to only approximately 4% of net assets. Cash and deposits of ¥14.04B exceeded current liabilities of ¥8.68B, indicating a conservative and robust financial foundation.

Cash Flow Analysis

Since figures from the statement of cash flows have not been disclosed, cash trends are assessed based on changes in the balance sheet. Cash and deposits were ¥14.04B, almost unchanged from ¥14.21B in the same period of the previous year, with no significant cash inflows or outflows observed. Meanwhile, accounts receivable and notes receivable increased to ¥7.56B from ¥7.12B in the previous year, confirming an accumulation of working capital associated with revenue growth. On the current liabilities side, advances received represented a significant component at ¥4.50B, compared with ¥4.44B in the previous year, indicating that contract-based advances are supporting a portion of the company’s liquidity. Investment in property, plant and equipment was ¥5.05B, essentially unchanged from ¥5.03B in the previous year, and there were no signs of large-scale capital investment. Overall, the fact that cash and deposits have not increased despite higher earnings suggests that the increase in trade receivables may be creating a time lag in cash generation.

Quality of Earnings

Of Ordinary Income of ¥0.92B, non-operating income and expenses contributed a surplus of only ¥0.06B, while Operating Income of ¥0.86B accounted for the majority of earnings. Accordingly, profit at the Ordinary Income level is of high quality because it is primarily derived from the core business. Extraordinary losses were immaterial at ¥0.001B, and the impact of temporary factors such as impairment losses on investment securities was limited. Pretax income of ¥0.91B therefore reflects the recurring earnings structure. Meanwhile, income taxes and other taxes amounted to ¥0.28B, resulting in a somewhat high effective tax rate. Compared with the strong growth in earnings at the Ordinary Income and Operating Income levels, this contributed to the slightly lower growth rate in Net Income attributable to owners of the parent (+49.3%). In addition, because the increase in revenue was accompanied by growth in accounts receivable, there may be a time lag between accounting profit growth and its cash backing. From an accrual perspective, it will be necessary to monitor the future collection of accounts receivable. Comprehensive income was ¥0.64B, approximately in line with Net Income, indicating that the impact of other comprehensive income items, such as foreign currency translation adjustments, was limited.

Earnings Forecast and Guidance

Progress toward the full-year earnings forecast was 24.9% for revenue (actual ¥6.73B/forecast ¥27.0B), 25.9% for Operating Income (¥0.86B/¥3.30B), and 26.1% for Ordinary Income (¥0.92B/¥3.50B), representing standard progress for Q1. Against the full-year forecast Operating Income margin of 12.2%, Q1 results were progressing at a slightly higher level of 12.7%. No revisions were made to the earnings forecast or dividend forecast during the quarter.

Shareholder Returns

The full-year dividend forecast is ¥130 per share, and the forecast Payout Ratio based on the full-year EPS forecast of ¥292.06 is approximately 44.5%. This level is below the general benchmark of 60%, and the dividend burden is not excessive even relative to the full-year Net Income forecast of ¥2.20B. The company holds ¥4.48B in treasury shares; however, the implementation status of share buybacks cannot be confirmed from the disclosed data. The Payout Ratio and Total Return Ratio therefore need to be evaluated separately. Cash and deposits of ¥14.04B and the low level of interest-bearing debt provide financial support for continued dividend payments. No revision was made to the dividend forecast during the quarter.

Risk Factors

1. Business concentration risk: The Water Healthcare Business accounts for 89.0% of consolidated revenue and approximately 92% of consolidated Operating Income. Consequently, changes in demand and the competitive environment in this business directly affect consolidated performance.

2. Working capital efficiency: Accounts receivable and notes receivable were ¥7.56B, large relative to revenue, while DSO was approximately 102 days and CCC was approximately 138 days, both relatively long. During a period of revenue growth, a time lag in cash generation may arise.

3. Tax burden and profit conversion: Income taxes and other taxes of ¥0.28B have somewhat constrained the growth in Net Income attributable to owners of the parent (+32.7%〜49.3%) relative to the strong increase in Operating Income and Ordinary Income (+45〜48%). Changes in the tax burden may therefore become a factor affecting fluctuations in Net Income.

Industry Benchmark (Reference; Company Analysis)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the Operating Income margin and Net Income margin exceed the industry median, placing the company’s profitability in the upper tier of the industry.

Growth and Capital Efficiency

The revenue growth rate substantially exceeds the industry median and is tracking near the upper bound of the IQR.

※Source: Company analysis

Key Takeaways from the Earnings Results

1. The Operating Income margin improved by +3.0pt YoY, confirming improved profitability in both the core Water Healthcare Business and the Medical-Related Business. The simultaneous progress in revenue growth and margin improvement is noteworthy as a qualitative change in the earnings structure.

2. The company continues to depend on the Water Healthcare Business for the majority of consolidated revenue and Operating Income. Trends in this business’s growth rate and segment profit margin will be critical to achieving the full-year plan.

3. Revenue growth was accompanied by an increase in accounts receivable, and a tendency toward lengthening DSO and CCC was observed. It will be useful to monitor future trends in accounts receivable to determine whether a divergence is emerging between accounting profit growth and the pace of cash generation.

Theoretical Share Price (Reference Value)

Sensitivity: ¥3,067〜¥3,243 at a ±1% change in the cost of equity, and ¥3,152〜¥3,154 at a ±0.1 change in ω.

Note:

• Net assets as of the end of the quarter are used (there is a time-period difference relative to the full-year forecast).

(Calculation model: Residual income model (Ohlson-type with an explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated values based solely on publicly disclosed data; these are not forecasts of the market share price or recommendations for specific investment actions, and do not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Nihon Trim delivered a strong FY2027 Q1 result, with revenue growth translating into substantially faster operating-profit growth. Revenue increased 13.1% year on year to ¥6.73bn. Operating income rose 48.4% to ¥0.86bn. Ordinary income increased 45.8% to ¥0.92bn, while profit attributable to owners of parent grew 32.7% to ¥0.53bn. The operating margin expanded by 303 basis points year on year to 12.7% from 9.7%. Gross margin eased by approximately 73 basis points to 67.3%, indicating that the earnings improvement was not driven by gross-margin expansion. Instead, SG&A as a percentage of revenue declined by approximately 374 basis points, as SG&A grew only 5.8% against 13.1% revenue growth. This operating leverage was the principal driver of the sharp operating-income increase. Water Healthcare, the core business, generated 89.0% of consolidated revenue and 92.0% of segment operating profit. Water Healthcare revenue increased 15.1% to ¥5.98bn and segment profit increased 43.5% to ¥0.79bn. Medical-related revenue was broadly flat at ¥0.75bn, but segment profit more than doubled to ¥0.07bn, albeit from a low base. The FY2027 full-year forecasts imply Q1 progress of 24.9% in revenue, 25.9% in operating income, and 24.2% in profit attributable to owners, all broadly in line with the standard 25% first-quarter run rate. The balance sheet remains highly liquid, supported by ¥14.04bn of cash and deposits and a 272.8% current ratio. Receivable collection and the cash conversion cycle remain the principal operating-finance areas requiring attention, with annualized DSO of 102 days and an annualized CCC of 138 days. The planned annual dividend of ¥130 per share implies a 44.5% payout ratio based on forecast EPS of ¥292.06, which appears compatible with the current earnings outlook and conservative interest-bearing debt level. Overall, the quarter supports the company’s full-year earnings trajectory, but sustaining SG&A discipline and improving working-capital efficiency will be important to convert accounting profit into cash generation.

Profitability Analysis

The reported annualized DuPont ROE is 8.5%, comprising a 7.9% net profit margin, 0.734x asset turnover, and 1.46x financial leverage. The return profile is driven primarily by solid margins and moderate asset utilization rather than aggressive balance-sheet leverage. Financial leverage is conservative, so the 8.5% annualized ROE has scope to improve mainly through sustained margin expansion and more efficient use of the asset base. The largest year-on-year change was in operating profitability: the operating margin increased to 12.7% from 9.7%, a 303bp improvement. Gross margin declined modestly to 67.3%, but SG&A intensity fell materially as SG&A rose 5.8%, well below 13.1% revenue growth. This indicates favorable operating leverage and disciplined cost absorption rather than price-led gross-margin expansion. Water Healthcare was the core business, contributing ¥5.98bn of revenue and ¥0.79bn of segment profit, with a 13.1% segment margin versus 10.6% a year earlier. Medical-related operations recorded ¥0.75bn of revenue and ¥0.07bn of segment profit; its margin improved to 9.2% from 3.7%, though revenue declined 1.0%. The consolidated net margin was 7.9%, within the good 5-10% range, while the 12.7% operating margin is also in the good range. The tax burden factor was 0.582, below the 0.60 caution threshold, because profit attributable to owners of parent was ¥0.53bn against ¥0.91bn of profit before tax. This measure incorporates ¥0.11bn of profit attributable to non-controlling interests; on a consolidated basis, income tax expense of ¥0.28bn represented 30.2% of profit before tax, indicating a more normal underlying tax charge. Interest burden was favorable at 1.069 and interest coverage was exceptionally strong at 553.0x, reflecting minimal financing cost.

Growth Assessment

Revenue growth was broad enough to support the full-year outlook, led by the Water Healthcare business. Water Healthcare sales increased ¥0.79bn year on year, accounting for the consolidated revenue increase of ¥0.78bn. Its segment profit rose ¥0.24bn, demonstrating strong incremental profitability from the sales expansion. Medical-related segment revenue declined by ¥0.01bn, but segment profit increased by ¥0.04bn, suggesting an improved cost and/or business mix. Consolidated gross profit increased 11.9% to ¥4.53bn, below revenue growth, but SG&A control more than offset the modest gross-margin pressure. Operating income therefore grew 48.4%, materially faster than revenue. Full-year company guidance calls for 11.8% revenue growth, 12.2% operating-income growth, and 11.2% ordinary-income growth. Q1 revenue progress of 24.9% is essentially in line with the standard first-quarter pace, while operating-income progress of 25.9% is modestly ahead. Profit attributable to owners progressed 24.2% against the full-year target, also close to the standard pace. The earnings base appears predominantly operating in nature: operating income of ¥0.86bn represented the overwhelming share of ordinary income of ¥0.92bn. Non-operating income was ¥0.07bn, equivalent to approximately 1.0% of revenue, and therefore does not materially alter the operating earnings picture. Gain on sale of non-current assets was ¥0.08bn, while extraordinary loss was ¥0.01bn; these items were small relative to profit attributable to owners and do not appear to be the main source of quarterly earnings growth.

Financial Health

Liquidity is strong. Current assets of ¥23.68bn covered current liabilities of ¥8.68bn, producing a current ratio and quick ratio of 272.8%. Cash and deposits of ¥14.04bn alone represented 161.7% of current liabilities. Working capital was ¥15.00bn, providing a sizable liquidity buffer. Total liabilities were ¥11.59bn against total equity of ¥25.09bn, and the reported debt-to-equity ratio was 0.46x, well below the 2.0x warning threshold. Interest-bearing debt consisted of ¥1.00bn of long-term loans, equivalent to approximately 4.3% of owners’ equity and 3.8% of capital. There is no apparent short-term debt maturity mismatch, as the reported interest-bearing debt is long term and current assets materially exceed current liabilities. Noncurrent liabilities included ¥4.31bn of net defined benefit liability, ¥3.02bn of directors’ retirement benefit provision, and ¥2.17bn of share-based-payment provision. Advances received were ¥4.50bn, forming a significant part of current liabilities and providing operating funding, though they also represent obligations to deliver products or services. Accounts payable increased 50.2% year on year to ¥0.93bn, exceeding the pace of sales growth; this supports near-term operating funding but should be monitored alongside supplier terms and inventory procurement. Equity declined 1.5% year on year to ¥25.09bn, while total assets increased 1.7% to ¥36.68bn. Goodwill was only ¥0.27bn, or 1.1% of equity and 0.7% of assets, leaving balance-sheet exposure to acquisition-value impairment low. Intangible assets were also limited at 1.5% of total assets.

Notable B/S Changes

Accounts payable: +¥0.31bn (+50.2%) to ¥0.93bn - growth materially exceeded revenue growth, improving short-term supplier financing but requiring monitoring of procurement timing and payment terms.

Cash Flow Quality

Dividend Sustainability

The company forecasts an annual dividend of ¥130 per share and forecast EPS of ¥292.06. This implies a dividend payout ratio of 44.5%, below the 60% sustainability benchmark. The planned dividend is supported by the Q1 earnings trajectory, with profit attributable to owners increasing 32.7% year on year to ¥0.53bn. The balance sheet also provides substantial financial flexibility, with ¥14.04bn of cash and deposits and only ¥1.00bn of interest-bearing debt. The 44.5% forecast payout leaves earnings retention capacity for working capital, investment, and shareholder distributions. Receivables and the cash conversion cycle should nevertheless be monitored closely because prolonged working-capital absorption could affect the pace at which accounting earnings become distributable cash. No dividend revision was announced.

Risk Assessment

Business risks include Water Healthcare concentration: the segment represented 89.0% of revenue and 92.0% of segment profit, so demand, channel, product-cycle, or competitive disruption in water ionizers and related products would have a disproportionate earnings effect., Medical-related business execution: segment profit improved sharply to ¥0.07bn despite a 1.0% revenue decline; maintaining this margin improvement depends on continued cost discipline and successful development of medical and regenerative-medicine activities., Manufacturing and product-quality exposure: raw materials were ¥1.10bn and finished goods were ¥0.70bn, while product-warranty provision was ¥0.09bn. Changes in input costs, inventory management, product quality, or warranty claims could pressure margins., Demand sensitivity and consumer-discretionary exposure in the Water Healthcare business may affect sales of household water-healthcare products and bottled water..

Financial risks include High receivable days: annualized DSO was 102 days, above the 60-day warning threshold. This indicates slow conversion of sales into customer cash receipts and raises counterparty-credit and collection-timing risk., Long cash conversion cycle: the annualized CCC was 138 days, above the 120-day warning threshold. The extended operating cash cycle can require more working capital as revenue expands., Accounts payable increased 50.2% year on year to ¥0.93bn, materially faster than sales. This may reflect procurement timing or greater use of supplier credit and should be assessed with payment terms., Investment securities totaled ¥3.04bn, or 8.3% of assets. Market-value movements can affect comprehensive income and equity; the quarter included a ¥0.05bn valuation loss in OCI..

Key concerns include The quality alert for high tax burden is driven by the 0.582 tax-burden factor calculated using profit attributable to owners. Its impact is less severe when assessed on consolidated pre-tax income, where the effective tax rate was 30.2%; however, non-controlling interests reduce the share of consolidated earnings attributable to parent shareholders., The quality alert for high receivable days has direct relevance for cash realization. At 102 annualized days, a further rise in receivables relative to sales would weaken cash conversion even if reported revenue remains strong., The quality alert for a 138-day annualized cash conversion cycle indicates that expansion may absorb operating capital. Improving collections and avoiding excess inventory accumulation are key to protecting financial flexibility., The FY2027 guidance assumes continued double-digit revenue growth. Q1 performance is aligned with that target, but the favorable SG&A leverage seen in Q1 must persist for the operating-margin gain to be sustained..

Investment Implications

Key takeaways include Q1 operating income growth of 48.4% substantially exceeded revenue growth of 13.1%, driven by a 303bp operating-margin expansion., Water Healthcare is the core earnings engine, delivering ¥5.98bn of revenue, ¥0.79bn of segment profit, and a 13.1% segment margin., Full-year guidance progress is broadly normal for Q1: 24.9% for revenue, 25.9% for operating income, and 24.2% for profit attributable to owners., Liquidity and debt capacity are strong, with a 272.8% current ratio, ¥14.04bn cash balance, 3.8% debt-to-capital, and 553.0x interest coverage., The principal financial-monitoring issue is working-capital efficiency, particularly 102 annualized receivable days and a 138-day annualized cash conversion cycle., The forecast dividend payout ratio of 44.5% is within a sustainable range based on forecast EPS and the present capital structure..

Metrics to watch include Water Healthcare revenue growth and segment margin, Medical-related revenue recovery and the durability of its 9.2% segment margin, Consolidated gross margin and SG&A-to-sales ratio, Annualized receivable days and cash conversion cycle, Accounts payable growth relative to sales and procurement activity, Progress against the ¥27.0bn revenue and ¥3.3bn operating-income full-year forecasts, Dividend coverage relative to forecast EPS of ¥292.06.

Regarding relative positioning, Nihon Trim combines good operating profitability, conservative leverage, and exceptional interest-service capacity. Its annualized ROE of 8.5% is above the caution threshold but below the 10-15% range generally associated with stronger return profiles. The company’s low goodwill exposure and high liquidity compare favorably with acquisition-heavy or highly leveraged peers, while its extended receivable and cash-conversion cycle is a relative operational weakness requiring attention.